Browsing by Autor "Piere Ray Tito Rodriguez"

Now showing 1 - 3 of 3

A Comparison of Cardiovascular Benefits of Dapagliflozin and Empagliflozin in Type 2 Diabetes: A Systematic Review and Meta-analysis
(Springer Nature, 2025) N. Benjamin; Aarushi Gupta; Tawfiq Turjman; Wajih Syed; Anand Anghan; Chenny Koodarath; Naseem Salahuddin; Mohammed M. Khawar; Anirudh Y. Edu; Piere Ray Tito Rodriguez
Diabetes Mellitus and Its Role in the Development and Progression of Atrial Fibrillation: A Review and Recommendations
(2023) Piere Ray Tito Rodriguez; Faris Fayyaz; Dharani Swarna Deiveegan; Dr.Aleena Arif; Husnain Bukhari; Gopi Sairam Reddy Mulaka; Navya Pillikunte Doddareddy; Osatohanmwen Ekomwereren; Hundaol Gemechu Atew; Saptarshi Mukherjee
Millions worldwide suffer from a chronic metabolic disorder called type 2 diabetes mellitus.Atrial fibrillation is the most common persistent arrhythmic condition that increases the risk of heart and brain complications.Recent studies depict that diabetic patients have a higher chance of developing AF, but the exact link between these two conditions is unclear.We discuss the current understanding of how AF and Diabetes are related based on the following aspects: electrical, electromechanical, structural, and oxidative stress changes, connexin remodeling, and glycemic fluctuations.Additionally, we explore other potential mechanisms, including inflammation, autonomic dysfunction, obesity, microvascular disease, metabolic factors, hyperglycemia, and renal dysfunction.We also summarize the clinical studies investigating the outcomes and management of patients with AF and Diabetes.We review the available treatment options, such as anti-diabetic and anti-arrhythmic drugs, and nonpharmacological interventions, such as cardioversion, catheter ablation, and direct current cardioversion.This review provides valuable insights into the multifaceted relationship between Diabetes mellitus and its role in the development and progression of atrial fibrillation, offering recommendations for understanding and managing this complex interplay.
Evolving Horizons in Pediatric Leukemia: Novel Insights, Challenges, and the Journey Ahead
(Cureus, Inc., 2024) Piere Ray Tito Rodriguez; Deepalee Mehta; Muhammad Subhan; Ratan Pal Yadav; Bibi Sarah Yousofzai; Ebtesam Al-Najjar; Ruqiya Bibi; Mohamed Idries; Atinder Singh; Muhammad Adnan
Pediatric leukemia, encompassing acute lymphoblastic leukemia (ALL) and acute myeloid leukemia, remains a formidable challenge despite significant treatment advancements. This review examines recent developments in immunotherapy, chemotherapy, and bone marrow transplantation for pediatric leukemia through a comprehensive analysis of recent literature, focusing on critical studies and clinical trials. Immunotherapy, including monoclonal antibodies, such as blinatumomab and inotuzumab ozogamicin, and chimeric antigen receptor T-cell therapies, such as tisagenlecleucel and brexucabtagene autoleucel, have demonstrated promising results in relapsed or refractory B-cell ALL (B-ALL), achieving notable remission rates with manageable side effects. Chemotherapy continues to be the primary treatment, utilizing multiphase regimens tailored to individual risk profiles. Bone marrow transplantation, especially allogeneic stem cell transplantation, offers potential cures for high-risk or relapsed cases, though it poses risks including graft-versus-host disease and infections. Despite these advancements, treatment resistance, toxicity, and accessibility persist. This review also discusses the long-term outcomes among pediatric leukemia survivors, focusing on late-onset side effects associated with treatments such as chemotherapy and bone marrow transplantation, encompassing secondary malignancies, organ dysfunction, and neurocognitive impacts. Ongoing research and clinical trials are crucial to refine these therapies, enhance their efficacy, and reduce adverse effects, ultimately improving young patients' survival and quality of life.